Bristol-Myers to buy heart drugs developer MyoKardia for about $13 bln
Oct 5 (Reuters) - U.S. drugmaker Bristol-Myers Squibb Co said on Monday it would buy heart drugs developer MyoKardia Inc for about $13 billion.
Bristol Myers will pay $225 per share in cash, a 61.2% premium to MyoKardia's Friday closing price. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty)
Terms and Privacy Policy